Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

822 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Gibson CM, et al. Among authors: burton p. N Engl J Med. 2016 Dec 22;375(25):2423-2434. doi: 10.1056/NEJMoa1611594. Epub 2016 Nov 14. N Engl J Med. 2016. PMID: 27959713 Free article. Clinical Trial.
Rivaroxaban in patients with a recent acute coronary syndrome.
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Mega JL, et al. Among authors: burton p. N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13. N Engl J Med. 2012. PMID: 22077192 Free article. Clinical Trial.
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GY, Cohen M, Peterson ED, Fox KA. Gibson CM, et al. Among authors: burton p. Circulation. 2017 Jan 24;135(4):323-333. doi: 10.1161/CIRCULATIONAHA.116.025783. Epub 2016 Nov 14. Circulation. 2017. PMID: 27881555 Free PMC article. Clinical Trial.
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Korjian S, Braunwald E, Daaboul Y, Verheugt F, Bode C, Tendera M, Jain P, Plotnikov A, Burton P, Gibson CM. Korjian S, et al. Among authors: burton p. Eur Heart J Acute Cardiovasc Care. 2019 Mar;8(2):186-193. doi: 10.1177/2048872617745003. Epub 2017 Dec 18. Eur Heart J Acute Cardiovasc Care. 2019. PMID: 29249166 Clinical Trial.
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
Korjian S, Braunwald E, Daaboul Y, Mi M, Bhatt DL, Verheugt FWA, Cohen M, Bode C, Burton P, Plotnikov AN, Gibson CM. Korjian S, et al. Among authors: burton p. Am J Cardiol. 2018 Dec 1;122(11):1896-1901. doi: 10.1016/j.amjcard.2018.08.034. Epub 2018 Sep 7. Am J Cardiol. 2018. PMID: 30340765 Free article. Clinical Trial.
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E; ATLAS-ACS 2 TIMI 51 Investigators. Gibson CM, et al. Among authors: burton p. J Am Coll Cardiol. 2013 Jul 23;62(4):286-90. doi: 10.1016/j.jacc.2013.03.041. Epub 2013 Apr 16. J Am Coll Cardiol. 2013. PMID: 23602776 Free article. Clinical Trial.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Khorana AA, et al. Among authors: burton p. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.
Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy.
Verheugt FW, Clemmensen P, Mehran R, Agewall S, Pocock SJ, Goldstein S, Torp-Pedersen C, Simoons ML, Borer JS, Khder YM, Burton P, Deliargyris E, McMurray JJ, Berkowitz SD, Stough WG, Zannad F. Verheugt FW, et al. Among authors: burton p. Eur Heart J. 2013 Jun;34(22):1621-9. doi: 10.1093/eurheartj/eht013. Epub 2013 Feb 4. Eur Heart J. 2013. PMID: 23382466 No abstract available.
The treatment of missing data in a large cardiovascular clinical outcomes study.
Little RJ, Wang J, Sun X, Tian H, Suh EY, Lee M, Sarich T, Oppenheimer L, Plotnikov A, Wittes J, Cook-Bruns N, Burton P, Gibson CM, Mohanty S. Little RJ, et al. Among authors: burton p. Clin Trials. 2016 Jun;13(3):344-51. doi: 10.1177/1740774515626411. Epub 2016 Feb 17. Clin Trials. 2016. PMID: 26908543
822 results